Craig, Zoe https://orcid.org/0000-0001-9930-6648
Swain, Jayne
Batman, Emma
Wadsley, Jonathan
Reed, Nicholas
Faluyi, Olusola
Cave, Judith
Sharma, Rohini
Chau, Ian
Wall, Lucy
Lamarca, Angela
Hubner, R
Mansoor, Wasat
Sarker, Debashis
Meyer, Tim
Cairns, David A
Howard, Helen
Valle, Juan W
McNamara, Mairéad G
Clinical trials referenced in this document:
Documents that mention this clinical trial
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC) (Pre-results)
https://doi.org/10.1136/bmjopen-2019-034527
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
https://doi.org/10.1200/jco.2023.41.4_suppl.646
Funding for this research was provided by:
Cancer Research UK (C7852/A25447)
Servier (016-34263)